Business Context and Reporting Period
This Form 8-K filing by National Research Corporation (NRC Health) reports on corporate governance changes announced on February 26, 2025. The filing details the appointment of a new Chief Executive Officer and an interim Principal Financial Officer, effective June 1, 2025, and March 31, 2025, respectively.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on executive appointments and compensation arrangements.
Material Changes
- Executive Leadership Transition: Trent Green is appointed as Chief Executive Officer and Director, effective June 1, 2025. Current CEO Micheal D. Hays will transition to the role of Chairman.
- Board Expansion: The Board of Directors size increases from six to seven members to accommodate Mr. Green.
- Interim CFO Appointment: Linda Stacy is appointed as Interim Principal Financial Officer until March 31, 2025, at a rate of $150 per hour.
Compensation and Outlook
The Talent and Compensation Committee approved the following package for Trent Green:
- Base Salary: $1,250,000 annualized.
- Equity Grant: 500,000 shares of common stock with specific repurchase and transfer restrictions tied to the third anniversary of the Effective Date.
- Signing Bonus: Cash bonus equal to 66 2/3% of the value of the equity grant based on the closing price prior to the Effective Date.
- Severance: One year of continued base salary payment if terminated without cause or resigning with good reason after the third anniversary.
Management notes that the filing contains forward-looking statements subject to risks and uncertainties, with actual results potentially differing from expectations.
Investor Verification Checklist
- Verify the exact closing stock price on the trading day prior to June 1, 2025, to calculate the cash signing bonus value.
- Confirm the specific vesting schedule and transfer restrictions for the 500,000 shares granted to Mr. Green.
- Monitor the transition timeline for Linda Stacy's interim role ending March 31, 2025, and the subsequent permanent CFO appointment.
- Review the press release (Exhibit 99.1) for additional details on Mr. Green's strategic vision not included in this summary.